India, South Africa, and Indonesia are pushing for strong language to highlight the lack of consensus on the matter during the 13th Ministerial Conference (MC13) of the World Trade Organization (WTO). The countries are advocating for a waiver on intellectual property rights for COVID-19 diagnostics and therapeutics, expressing their concerns about the unequal access and affordability of these vital tools. Despite opposition from some countries, including developed nations, the three countries continue to assert the need for a waiver to ensure the availability of affordable and accessible healthcare solutions in the face of the ongoing pandemic. They argue that such a waiver is crucial to achieving global solidarity and ensuring equal access to life-saving treatments for all nations. The debate on intellectual property rights and access to essential health technologies has been a significant point of contention during the COVID-19 crisis, with many lower-income countries struggling to secure affordable diagnostics and therapeutics due to high costs and limited production capacity. India being one of the world’s largest producers of generic medicines and vaccines, and South Africa having experienced challenges in procuring affordable medicines in the past, make them crucial advocates for the waiver. Indonesia, on the other hand, has also faced challenges in accessing affordable healthcare solutions, especially for its vast population. Recognizing the urgency of addressing the global health crisis, the three countries have been consistent in their efforts to highlight the need for a waiver to facilitate the scaling up of production and ensure equitable distribution of COVID-19 diagnostics and therapeutics. Amidst the ongoing negotiations, India, South Africa, and Indonesia are determined to push for strong and decisive language in the outcomes of the WTO MC13, reflecting the importance of addressing the lack of consensus and the urgent need to promote access to affordable healthcare for all.